Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Expanding Access to High-Quality Healthcare

Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its...

Impetus Digital

- PMLiVE

Merck and Proxygen partner in deal worth up to $2.5bn

The companies will identify molecular glue degraders against multiple therapeutic targets

- PMLiVE

NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer

Up to 15% of patients with differentiated thyroid cancer do not respond to radioactive iodine

- PMLiVE

Sartorius signs agreement to acquire Polyplus for €2.4bn

The deal is expected to close during the third quarter of this year

- PMLiVE

Why diagnostics investments are crucial to win the AMR battle

AMR could take the lives of ten million people a year within three decades

- PMLiVE

Innovative Trials nominates Eloise Moffett as New VP of Commercial

Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally

Innovative Trials

- PMLiVE

UK launches ‘revolutionary’ trial for progressive MS patients

Octopus is assessing whether existing drugs can be used to help slow disease progression

- PMLiVE

Johnson & Johnson offers $8.9bn to resolve all talcum powder lawsuits

The company faces more than 38,000 lawsuits alleging that its talc products cause cancer

- PMLiVE

Outsmarting unpredictability: using scenario planning to keep ahead

Scenario planning is now considered an essential tool to navigate uncertainty with confidence

- PMLiVE

The ever-shifting landscape of health wearables

Back in 2018, we published a whitepaper discussing the growing trend of wearables in healthcare, along with the impact that this could potentially have on both patients and the healthcare...

IGNIFI

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

Johnson & Johnson’s strategy to resolve talcum powder lawsuits blocked by US appeals court

The company faces more than 38,000 lawsuits alleging that its talc products contain asbestos

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links